Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 | 1 | Northwestern UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00899431 |
| Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) |
| terminated |
| Phase 2 |
| 39 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jan 27, 2020 |
| clinicaltrials |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT02435550 | iCare for Cancer Patients | terminated | N/A | 136 | University of FloridaOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | terminated | Phase 1 / Phase 2 | 22 | Innate PharmaINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | terminated | Phase 1 | 2 | Michael ChoiOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 18 | Albert Einstein College of MedicineOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | terminated | Phase 1 / Phase 2 | 202 | Gilead SciencesINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | terminated | Phase 3 | 161 | Gilead SciencesINDUSTRY | 5 | Aug 20, 2019 | clinicaltrials |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | terminated | Phase 1 / Phase 2 | 3 | University of California, San DiegoOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 261 | Gilead SciencesINDUSTRY | 11 | Aug 14, 2019 | clinicaltrials |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | terminated | Phase 2 | 2 | Children's Mercy Hospital Kansas CityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | terminated | Phase 2 | 3 | St. Jude Children's Research HospitalOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | terminated | Phase 1 | 1 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT02989675 | SugarFACT - Sugar Requirements For African Children Trial | terminated | N/A | 410 | Helena HildenwallOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 / Phase 2 | 9 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 57 | Gilead SciencesINDUSTRY | 8 | Nov 19, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 | clinicaltrials |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | terminated | Phase 2 | 105 | Gilead SciencesINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | terminated | Phase 2 | 135 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)(AHCTALL) | terminated | Phase 2 | 100 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | terminated | — | 200 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)(ATLAS2015) | terminated | — | 20 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL | terminated | Phase 1 | 14 | ERYtech PharmaINDUSTRY | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | — | 56 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | terminated | Phase 1 / Phase 2 | 29 | University College, LondonOTHER | 2 | May 17, 2018 | clinicaltrials |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 2, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | terminated | Phase 2 | 74 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients(VAY736Y) | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2018 | clinicaltrials |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) | terminated | Phase 2 | 22 | MorphoSys AGINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2020source: clinicaltrials